From Wikipedia, the free encyclopedia
(Redirected from 6-API)
Chemical compound
Pharmaceutical compound
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H14N2 |
| Molar mass | 174.247 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
6-(2-Aminopropyl)indole (6-API, 6-IT) is an indole derivative which was first identified being sold on the designer drug market by a laboratory in the Czech Republic in July 2016.[2]
Alexander Shulgin says in his book TiHKAL "From the normal 3-position to the 2, the 4, the 5, the 6 or the 7-positions. All five alpha-methyltryptamine isomers are known, but only one is known to be active in man as a CNS active material. This is the 5-isomer, 5-(2-aminopropyl)indole or 5-IT"[1].
Pharmacology
[edit]Studies in dogs have shown the drug to increase hemoglobin levels in the bloodstream.[3]
Society and culture
[edit]Legal status
[edit]- 6-API is a positional isomer of αMT, and as such may be covered by the analogue act in the USA (depending on the nature of its psychoactive effect).
- 6-API / 6-IT is illegal in the UK, as it was banned as a temporary class drug in June 2013, along with 9 other related compounds.[4] On March 5, 2014, the UK Home Office announced that 6-API would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.[5]
- 6-API is covered by the Australian analogue act as an analogue of MDA "by the replacement of up to 2 carbocyclic or heterocyclic ring structures with different carbocyclic or heterocyclic ring structures"[6]
- 6-API is uncontrolled in Germany, as indole rings are not included as rings under the 2-phenethylamine derived section of the NPsG.[1]
See also
[edit]References
[edit]- ^ a b "New Psychoactive Substances Act (Neue-psychoaktive-Stoffe-Gesetz) (NpSG) Non-official translation" (PDF). Retrieved 9 November 2021.
- ^ Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA
- ^ Maxwell GM (September 1964). "The effects of an indole derivative 692'-amino-propyl indole) on the general and coronary haemodynamics of the intact dog". Experientia. 20 (9): 526–7. doi:10.1007/BF02154095. PMID 5856353. S2CID 7574163.
- ^ "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 Jun 2013. Retrieved 2013-07-11.
- ^ UK Home Office (2014-03-05). "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Government. Retrieved 2014-03-11.
- ^ "Criminal Code Act 1995" (PDF). Australian Government. 2009-08-05. Retrieved 2012-02-08.
PAGE 503
External links
[edit]| Adamantanes | |
|---|---|
| Adenosine antagonists | |
| Alkylamines | |
| Ampakines | |
| Arylcyclohexylamines | |
| Benzazepines | |
| Cathinones |
|
| Cholinergics |
|
| Convulsants | |
| Eugeroics | |
| Oxazolines | |
| Phenethylamines |
|
| Phenylmorpholines | |
| Piperazines | |
| Piperidines |
|
| Phenethylpyrrolidines | |
| Racetams | |
| Psychedelics | |
| Tropanes |
|
| Tryptamines | |
| Others |
|
| DRAsTooltip Dopamine releasing agents |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRAsTooltip Norepinephrine releasing agents |
| ||||||||||||||
| SRAsTooltip Serotonin releasing agents |
| ||||||||||||||
| Others |
| ||||||||||||||
| Phenethylamines |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphetamines |
| ||||||||||||||||
| Phentermines |
| ||||||||||||||||
| Cathinones |
| ||||||||||||||||
| Phenylisobutylamines (and further-extended) | |||||||||||||||||
| Catecholamines (and close relatives) |
| ||||||||||||||||
| Cyclized phenethylamines |
| ||||||||||||||||
| Related compounds |
| ||||||||||||||||
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Short description is different from Wikidata
- Drugs with non-standard legal status
- Wikipedia articles needing clarification from November 2021
- All articles with unsourced statements
- Articles with unsourced statements from November 2021
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles containing unverified chemical infoboxes
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
